[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100612682":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":20,"locations":26,"responsibleParty":42,"collaborators":44,"id":47,"slug":48,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":19,"eligibilityCriteria":53,"healthyVolunteers":49,"sex":54,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":19,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":19,"overallStatus":29,"whyStopped":19,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},{"fullName":5,"class":6},"Shanghai Juncell Therapeutics","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"GC203 TIL","EXPERIMENTAL","participants with advanced solid tumors using cryopreserved GC203 TIL",[13],"Biological: GC203 TIL",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"BIOLOGICAL","A tumor sample is resected from each participant and cultured ex vivo to expand the population of engineered tumor infiltrating lymphocytes injection (GC203 TIL). After lymphodepletion, patients are infused GC203 TIL.",[9],null,[21],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},"Ying Cheng","CONTACT","+8621-69110327","ying.cheng@juncell.com",[27],{"facility":28,"status":29,"city":30,"state":19,"zip":19,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"Shenzhen Hospital of Southern Medical University","RECRUITING","Shenzhen","China","CN",{"type":34,"coordinates":35},"Point",[36,37],114.0683,22.54554,{"lat":37,"lon":36},[40],{"name":41,"role":23,"phone":19,"phoneExt":19,"email":19},"Xin Li",{"type":43,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR",[45],{"name":28,"class":46},"OTHER","100612682","phase-1-a-study-of-gc203-til-in-advanced-solid-tumors-nf-100612682",false,"NCT07256756","A Study of GC203 TIL in Advanced Solid Tumors (NF)","A Phase I Study of Engineered Tumor Infiltrating Lymphocytes Injection (GC203 TIL) in Patients With Advanced Solid Tumors","Inclusion Criteria:\n\n* have one the tumor resection for gene-edited GC203 TIL production and successfully produced；\n* Age: 18 years to 75years;\n* Histologically diagnosed as solid tumor;\n* Expected life-span more than 3 months;\n* ECOG score 0-1;\n* Test subjects have failed standard treatment regimens, and be willing to receive engineered GC203 TIL therapy;\n* At least 1 evaluable tumor lesion;\n\nExclusion Criteria:\n\n* with other malignant tumors,except for the malignancies that have been cured, have been inactive for ≥5 years prior to study inclusion and have a very low risk of recurrence; Non-melanoma skin cancer or malignant lentigo with adequate treatment and no evidence of disease recurrence; Carcinoma in situ with adequate treatment and no evidence of disease recurrence;\n* Need glucocorticoid treatment, and daily dose of Prednisone greater than 10mg(or equivalent doses of hormones) or outoimmune diseases requiring immunomodulatory treatment;\n* Breathe indoor air in a quiet state, and the oxygen saturation of finger pulse is \\\u003C 95%;\n* Human immunodeficiency virus (HIV) infection or anti-HIV antibody positive, active HBV or HCV infection (HBsAg positive and\u002For anti-HCV positive), syphilis infection or Treponema pallidum antibody positive;\n* Significant cardiovascular anomalies","ALL","18 Years","75 Years",{"count":58,"type":59},8,"ESTIMATED","INTERVENTIONAL",[62],"PHASE1","This study is a prospective, open-label, single-arm clinical trial aimed at evaluating the safety and efficacy of GC203 TIL therapy in treating malignant solid tumors that have failed standard treatment.",[65],"Solid Tumors, Adult","2026-08-03",{"date":68,"type":69},"2026-08-05","ACTUAL",{"date":71,"type":69},"2026-01-30",{"date":73,"type":59},"2028-11-30",{"name":5,"class":6},1]